With Muted Expectations For Provenge, Dendreon Restructures, Cuts Staff
This article was originally published in The Pink Sheet Daily
Executive Summary
A quarter of its employees, including the COO and many in manufacturing and administrative positions, will be dismissed.
You may also be interested in...
Korea’s Green Gross, Russia’s Pharmstandard Lead $42.5M Argos Financing; Take Local Rights
The personalized immunotherapy developer partnered with Korea’s Green Cross and Russia’s Pharmstandard but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights
The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
Clinical Stage Biotechs For Sale?
The oversized price tag attached to the recent acquisition of Pharmasset by Gilead has caused many to wonder how the take-out fits into historical patterns – or if it’s as big an outlier as it seems.